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In view of the importance of Candida drug resistance protein (Cdr1p) in azole resistance, we have charac-
terized it by overexpressing it as a green fluorescent protein (GFP)-tagged fusion protein (Cdr1p-GFP). The
overexpressed Cdr1p-GFP in Saccharomyces cerevisiae is shown to be specifically labeled with the photoaffinity
analogs iodoarylazidoprazosin (IAAP) and azidopine, which have been used to characterize the drug-binding
sites on mammalian drug-transporting P-glycoproteins. While nystatin could compete for the binding of IAAP,
miconazole specifically competed for azidopine binding, suggesting that IAAP and azidopine bind to separate
sites on Cdr1p. Cdr1p was subjected to site-directed mutational analysis. Among many mutant variants of
Cdr1p, the phenotypes of F774A and F774 were particularly interesting. The analysis of GFP-tagged mutant
variants of Cdr1p revealed that a conserved F774, in predicted transmembrane segment 6, when changed to
alanine showed increased binding of both photoaffinity analogues, while its deletion (F774), as revealed by
confocal microscopic analyses, led to mislocalization of the protein. The mislocalized F774 mutant Cdr1p
could be rescued to the plasma membrane as a functional transporter by growth in the presence of a Cdr1p
substrate, cycloheximide. Our data for the first time show that the drug substrate-binding sites of Cdr1p
exhibit striking similarities with those of mammalian drug-transporting P-glycoproteins and despite differ-
ences in topological organization, the transmembrane segment 6 in Cdr1p is also a major contributor to drug
substrate-binding site(s).
Candida albicans is an opportunistic diploid fungus that
causes infections in immunocompromised and debilitated pa-
tients (34). Widespread and prolonged usage of azoles in re-
cent years has led to the rapid development of the phenome-
non of multidrug resistance (MDR), which poses a major
hurdle in antifungal therapy. Various mechanisms which con-
tribute towards the development of MDR have been impli-
cated in Candida, and some of these include overexpression of
or mutations in the target enzyme of azoles, lanosterol 14-
demethylase, and overexpression of drug efflux pumps (1, 33)
belonging to the ATP-binding cassette (ABC) transporter
channel superfamily (18) and to the major facilitator super-
family of transporters (MFS) (22, 35). Among ABC transport-
ers, CDR1 has been shown to play a key role in azole resistance
in C. albicans as deduced from its high level of expression
found in several azole resistance clinical isolates recovered
from patients receiving long-term antifungal therapy (41, 39).
Additionally, high-level expression of CDR1 invariably contrib-
utes to an increased efflux of fluconazole, thus corroborating its
direct involvement in drug efflux (24, 38). Cdr1p has not only
acquired significant clinical importance but is considered an
important player in any design of strategies to combat antifun-
gal resistance.
The CDR1 gene encodes an integral plasma membrane
(PM) protein of 1,501 amino acids, with a predicted molecular
mass of 169.9 kDa. On the basis of its amino acid sequence,
Cdr1p is predicted to consist of two homologous halves, each
comprising one N-terminal hydrophilic domain followed by a
C-terminal hydrophobic domain. The hydrophilic domain
comprised a conserved ABC region, including the ATP-bind-
ing motifs known as the Walker A and Walker B motifs (48)
and another highly conserved motif, ABC signature, preceding
the Walker B motif (36). Cdr1p has a similar topology to its
close homologues Pdr5p and Snq2p of Saccharomyces cerevi-
siae (36).
According to our current understanding, Cdr1p and Cdr2p
drug extrusion proteins not only efflux azoles and its derivatives
but also extrude a variety of structurally unrelated drugs. Over-
expression of homologous ABC multidrug transporter pro-
teins, human P-glycoprotein (P-gp) or the MDR-associated
protein 1 (MRP1) is also responsible for the molecular basis of
the MDR phenotype in tumor cells (3). The molecular mech-
anisms which govern Cdr1p functions are not well-known, and
information is needed (i) to understand how the protein can
bind a structurally diverse range of compounds, (ii) to define
drug substrate binding, and (iii) to determine how ATP bind-
ing and hydrolysis are linked to drug transport.
In an effort to develop an understanding of the molecular
details of drug binding and the importance of domains in
Cdr1p, in this study we have overexpressed Cdr1p as a green
fluorescent protein (GFP)-tagged fusion protein (Cdr1p-GFP)
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in a heterologous system and for the first time characterized it
for drug and nucleotide binding. The GFP-tagged Cdr1p was
functionally similar to its untagged version, as it imparted drug
resistance to S. cerevisiae cells, showed ATPase activity, and
effluxed Cdr1p substrates, such as rhodamine 6G. Photoaffinity
P-gp substrate analogues were used to assess the drug sub-
strate sites of Cdr1p. For this, we used iodoarylazidoprazosin
(IAAP, a photoaffinity analogue of the P-gp substrate, prazo-
sin) and azidopine (a dihydropyridine photoaffinity analogue),
which are known to bind specifically to the human and murine
drug transporting P-gps. Our study demonstrates that both
IAAP and azidopine bind specifically to Cdr1p-GFP. Interest-
ingly, IAAP binding was competed out by nystatin, while azi-
dopine binding could only be competed out by miconazole,
thus demonstrating the possibility of different drug-binding
sites for the two analogues.
For functional analysis, mutations were introduced in pre-
dicted nucleotide-binding domain 1 (NBD1), transmembrane
segment 6 (TMS6), NBD2, cytoplasmic loop 5 (CL5), and
extracellular loop 6 (EL6). On the basis of phenotypic analysis,
two mutants in TMS6 (F774A and F774) were subjected to
detailed analysis by overexpressing them as GFP-tagged pro-
teins. Of note, the substitution of F774 with A in TMS6 re-
sulted in a selective loss of functional activity of the mutated
protein, while a deletion of the same phenylalanine (F774)
led to improper localization of the mutant protein. Our results
further show that if mutant cells in which F774 had been
deleted were grown in the presence of cycloheximide, it led to
the appearance of a functional transporter at the cell surface.
It appears that F774 in TMS6 is important for the localization
of Cdr1p.
MATERIALS AND METHODS
Materials. Anti-GFP monoclonal antibody was purchased from BD Bio-
sciences Clontech, Palo Alto, Calif. DNA-modifying enzymes were purchased
from Roche Molecular Biochemicals. Protease inhibitors, miconazole, nystatin,
cycloheximide, anisomycin, rhodamine 6G, and other molecular grade chemicals
were obtained from Sigma Chemical Co. (St. Louis, Mo.). The radiolabeled
[125I]IAAP (2,200 Ci/mmol) was from Perkin-Elmer Life Sciences (Boston,
Mass.). [-32P]8-azido-ATP (15 to 20 Ci/mmol) was from Affinity Labeling Tech-
nologies, Inc. (Lexington, Ky.), and [3H]azidopine (60 Ci/mmol) was from Am-
ersham Biosciences (Arlington Heights, Ill.). The [-32P]8-azido-ATP showed no
detectable contaminating [-32P]8-azido-ADP using thin-layer chromatography
with 0.8 M LiCl as the solvent. Fluconazole was kindly provided by Pfizer
(Sandwich, Kent, United Kingdom) and Ranbaxy Laboratories, New Delhi,
India.
Bacterial and yeast strains and growth media. Plasmids were maintained in
Escherichia coli XL-1 blue. E. coli was cultured in Luria-Bertani medium (Difco,
BD Biosciences) to which ampicillin was added (100 g/ml). The S. cerevisiae
strains used were AD1234568 (provided by A Goffeau, Universite´ Catholique de
Louvain in Belgium), AD1-8u, and AD1002 (provided by Richard D. Cannon,
University of Otago, Dunedin, New Zealand). SS1 to SS18 were AD1234568
derivatives expressing mutant Cdr1ps (Table 1). PSCDR1-GFP, SS5G (F774A),
and SS6G (F774) were AD1-8u derivatives expressing Cdr1p-GFP and its
mutant proteins (mutant Cdr1p-GFPs) (Table 1). The yeast strains were cultured
in yeast extract-peptone-dextrose (YEPD) broth (Bio 101, Vista, Calif.) or SD-
URA medium (Bio 101). For agar plates, 2% (wt/vol) Bacto agar (Difco, BD
Biosciences) was added to the medium.
Generation of polyclonal antibody to Cdr1p. The peptide CQSNKISKKEK
DDYVDY (amino acids 965 to 979, part of the putative NBD2), which repre-
sented the predicted most antigenic epitope of Cdr1p, was commercially synthe-
sized and conjugated to keyhole limpet hemocyanin by Princeton Biomolecules.
The antisera were raised in a New Zealand White rabbit after injecting 250 g
TABLE 1. Strains used in this study
Strain Genotype Strainderivation Reference
AD1234568 MATa pdr1-3 his1 ura3 yor1::hisG snq2::hisG
pdr5::hisG pdr10::hisG pdr11::hisG ycf1::hisG
pdr15::hisG
Decottignies et al. (9)
AD-CDR1 AD1234568 transformant carrying cloned CDR1 with
its native promoter in pYEURA3 (centromeric)
vector
AD1234568 This study
S6-20 AD1234568 transformant carrying only the
pYEURA3 (centromeric) vector
AD1234568 This study
AD1-8u MATa pdr1-3 his1 ura3 yor1::hisG snq2::hisG
pdr5::hisG pdr10::hisG pdr11::hisG ycf1::hisG
pdr3::hisG pdr15::hisG
Nakamura et al. (33)
AD1002 MATa pdr1-3 his1 ura3 yor1::hisG snq2::hisG
pdr5::PDR5PROM-CDR1-CDRISTOP
pdr10::hisG pdr11::hisG ycf1::hisG pdr3::hisG
pdr15::hisG
Nakamura et al. (33)
PSCDR1-GFP MATa pdr1-3 his1 ura3 yor1::hisG snq2::hisG
pdr5::PDR5PROM-CDR1-GFP-GFPSTOP
pdr10::hisG pdr11::hisG ycf1::hisG pdr3::hisG
pdr15::hisG
AD1-8u This study
SS1 to SS18 AD1234568 transformant carrying cloned mutant
CDR1 (SS1 to SS18 as described in the legend to
Fig. 3b) with its native promoter in pYEURA3
(centromeric) vector
AD1234568 This study
SS5G (F774A) MATa pdr1-3 his1 ura3 yor1::hisG snq::hisG
pdr5::PDR5PROM-CDR1(F774A)-GFP-GFPSTOP
pdr10::hisG pdr11::hisG ycf1::hisG pdr3::hisG
pdr15::hisG
AD1-8u This study
SS6G (F774) MATa pdr1-3 his1 ura3 yor1::hisG snq::hisG
pdr5::PDR5PROM-CDR1(F774)-GFP-GFPSTOP
pdr10::hisG pdr11::hisG ycf1::hisG pdr3::hisG
pdr15::hisG
AD1-8u This study
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of conjugated peptide and giving a booster dose after 2 months. The antiserum
was collected after 2 months (done by Covance Research Products, Inc.) and
used at a dilution of 1:500 for Western blot analysis.
Molecular cloning. A GFP tag was attached at the C-terminal end of CDR1.
The GFP open reading frame (ORF) was amplified from plasmid pGFP31 (31)
(a kind gift from Joachim Morschhauser, Zentrum fu¨r Infectionsforschung, Uni-
versita¨t Wu¨rzburg, Wu¨rzburg, Germany) using the following primers. The for-
ward primer was 5-ACGCGTCGACATGAGTAAGGGAGAAGAA-3 (the
SalI site is shown in bold type), and the reverse primer was 5-ACGCGTCGAC
GGACTAGTTTATTTGTATAGTTCATCCA-3 (the SalI site is shown in bold
type, and the SpeI site is shown in bold italic type). This GFP amplicon was
digested with SalI restriction enzyme. The stop codon of CDR1 was replaced with
a SalI site in p425-GPD-CDR1 (kind gift from Martine Raymond, Institut de
Recherches Cliniques de Montre´al, Montre´al, Que´bec, Canada). It was then
digested with SalI, and the digested GFP amplicon was ligated to the C-terminal
end of CDR1. The resulting CDR1-GFP ORF was taken out of the vector
p425-GPD-CDR1GFP by SpeI restriction enzyme and cloned in the vector pSK-
PDR5 PPUS (33) (kind gift from R. D. Cannon) at the SpeI site resulting in
plasmid pPSCDR1-GFP. After every cloning, the orientation was checked by
restriction enzyme digestion and sequencing using the Big Dye Terminator cycle
sequencing kit (ABI) and ABI 310 DNA sequencer.
Site-specific mutagenesis and development of transformants. Site-directed
mutagenesis was performed by using the QuikChange mutagenesis system from
Stratagene (La Jolla, Calif.). The mutations were introduced into plasmid
pS12-35 and pPSCDR1-GFP according to the manufacturer’s instructions, and
the desired nucleotide sequence alterations were confirmed by DNA sequencing
of the ORF. The mutated plasmid pS12-35 or the mutated pPSCDR1-GFP after
linearizing with XbaI was used to transform AD1234568 or AD1-8u cells,
respectively, for uracil prototrophy by the lithium acetate transformation proto-
col (2).
Genomic DNA extraction and Southern analysis of CDR1 gene in S. cerevisiae.
Plasmid or genomic DNA was isolated from S. cerevisiae cells as described
previously (19, 47). Genomic DNA was digested with restriction endonuclease
(EcoRV, BamHI, and PstI; Roche Biochemicals). Plasmid DNA (5 g) or di-
gested genomic DNA (10 g) was separated on a 1% agarose gel and transferred
to a Hybond nylon membrane (Amersham). Membranes were hybridized with
[-32P]dATP-labeled CDR1-specific probe (ORF nucleotides 1 to 280) under
high-stringency conditions (40).
Immunodetection of Cdr1p in PM. Crude membranes (CM) were prepared
from S. cerevisiae cells grown in YEPD to late exponential phase. The cells were
broken with glass beads by vortexing the cells four times for 30 s each time,
followed by a 30-s interval on ice. The homogenization medium contained 50
mM Tris (pH 7.5), 2.5 mM EDTA, and the protease inhibitor cocktail (1 mM
phenylmethylsulfonyl fluoride, 1 g of leupeptin per ml, pepstatin A, and apro-
tinin). The CM were recovered by centrifuging at 1, 000  g to remove unbroken
cells and pelleting the CM by ultracentrifugation at 100,000  g for 1 h. The CM
were resuspended in resuspension buffer (10 mM Tris [pH 7.5], 0.5 mM EDTA,
10% glycerol). The CM were applied to a discontinuous gradient made of an
equal volume of 53.5% (wt/vol) sucrose and 43.5% (wt/vol) sucrose. Following
centrifugation for 5 h at 100,000 g in a Beckman SW 28 rotor, the purified PMs
were recovered at the interface of the 43.5 and 53.5% sucrose layers by the
method of Monk et al. (30). The protein samples (20 g) were separated on
sodium dodecyl sulfate (SDS)–8% polyacrylamide gels and either stained with
colloidal Coomassie blue G250 or electroblotted (40 V, 1 h, 4°C) onto nitrocel-
lulose membranes (Invitrogen Life Technologies). The membranes were incu-
bated with anti-Cdr1p polyclonal antibody (diluted 1:500), anti-Pma1p poly-
clonal antibody (diluted 1:10,000), or anti-GFP monoclonal antibody (diluted
1:1,000). Immunoreactivity of Cdr1p and Pma1p antibodies was detected with
horseradish peroxidase (HRP)-labeled goat anti-rabbit antibody, which was di-
luted 1:20,000 in 20% fat-free milk. Immunoreactivity of GFP antibody was
detected with an anti-mouse antibody, which was diluted 1:10,000 in 5% fat-free
milk. Proteins on immunoblots were visualized using the enhanced chemilumi-
nescence assay system (ECL kit; Amersham Biosciences).
Drug susceptibility of S. cerevisiae. The susceptibilities of S. cerevisiae cells to
different drugs were determined by microtiter and spot assays as described
earlier (32).
ATPase assay. Cdr1p-associated ATPase activity of the purified PM was mea-
sured as an oligomycin-sensitive release of inorganic phosphate. Membrane
suspension (10 g of PM protein as determined by amido black B protein
estimation) (46) was incubated at 30°C in 0.1 ml of a medium containing 59 mM
Tris (pH 7.5) and 7 mM MgCl2 (ATPase assay buffer) and 20 M oligomycin
where indicated. To eliminate possible contributions from nonspecific phospha-
tases and vacuolar and mitochondrial ATPases, 0.2 mM ammonium molybdate,
50 mM KNO3, and 10 mM NaN3, respectively, were included in the reaction
mixture. The reaction was started by the addition of 5 mM ATP and was stopped
by the addition of 0.1 ml of 5% SDS solution. The amount of inorganic phos-
phate released was immediately determined as described previously (42).
Rhodamine 6G efflux. The efflux of rhodamine 6G was determined essentially
by a previously described protocol (29). Approximately 107 cells from a culture
grown overnight were inoculated in 250 ml of YEPD and grown for 5 h at 30°C.
The cells were pelleted and washed three times with phosphate-buffered saline
(PBS) without glucose. The cells were subsequently resuspended as a 2% cell
suspension in PBS to which rhodamine 6G was added to a final concentration of
10 M and incubated for 2 h at 30°C. The cells were then washed and resus-
pended in PBS with 2% glucose. An aliquot of 1 ml was taken after 45 min and
centrifuged at 9,000  g for 2 min. The absorbance of the supernatant was
measured at 527 nm.
Confocal microscopy. The cells were grown in SD-URA medium to late log
phase. The drugs were added 4 h after the inoculation as indicated. The cells
were washed and resuspended in an appropriate volume of 50 mM HEPES (pH
7.0). The cells were placed on the glass slides, and a drop of antifade reagent
(Fluoroguard high-performance antifade reagent; Bio-Rad, Hercules, Calif.) was
added to prevent photobleaching. The cells were directly viewed with a Bio-Rad
confocal microscope (MRC 1024) with a 100 oil immersion objective.
Flow cytometry of the cells. Flow cytometric analysis of the Cdr1p-GFP-
carrying S. cerevisiae cells was performed with a FACSort flow cytometer (Bec-
ton-Dickinson Immunocytometry Systems, San Jose, Calif.). Cells were grown to
mid-log phase, and 106 cells were harvested and washed with 50 mM HEPES (pH
7.0). Cells were resuspended in 500 l of 50 mM HEPES (pH 7.0). Ten thousand
cells were analyzed in acquisition. Analysis was performed with CellQuest soft-
ware (Becton-Dickinson Immunocytometry Systems). The mean fluorescence
intensity was calculated using the histogram stat program.
Photoaffinity labeling with IAAP. The PM proteins (15 g) were incubated
with the indicated competing drug for 10 min at 37°C in 50 mM Tris-HCl (pH
7.5). The samples were brought to room temperature, and 3 to 6 nM [125I]IAAP
(2,200 Ci/mmol) was added and incubated for an additional 5 min under subdued
light. The samples were then illuminated with a UV lamp assembly (PGC
Scientifics, Gaithersburg, Md.) fitted with two black light (self-filtering) UV-A
long-wavelength F15T8BLB tubes (365-nm wavelength) for 10 min at room
temperature (21 to 23°C). Following SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) on an 8% Tris-glycine gel at constant voltage, gels were dried and
exposed to Bio-Max MR film (Eastman Kodak, Rochester, N.Y.) at80°C for 12
to 24 h. The radioactivity incorporated into the Cdr1p band was quantified using
the STORM 860 PhosphorImager system (Molecular Dynamics, Sunnyvale,
Calif.) and the software ImageQuaNT as described previously (44).
Photoaffinity labeling with [3H]azidopine. The PM proteins (30 g) were
incubated with the indicated competing drug for 10 min at 37°C in 50 mM
Tris-HCl (pH 7.5). The samples were brought to room temperature and treated
with 0.5 M [3H]azidopine (60 Ci/mmol) for 5 min and then photo-cross-linked
at 365 nm at room temperature (21 to 23°C) for 10 min, and 5 SDS sample
buffer was added. Following electrophoresis, the gel was incubated with Fluro-
Hance (Research Products Inc.) for 30 to 45 min and dried under vacuum, and
the dried gel was exposed to an X-ray film for 3 to 6 days at 80°C. The
radioactivity incorporated into the Cdr1p band was quantified as described
above.
Binding of [-32P]8-azido-ATP. The PM protein (15 g) was incubated in the
ATPase assay buffer containing 10 M [-32P]8-azido-ATP (10 Ci/nmol) in the
dark at 4°C for 5 min in the presence or absence of 10 mM ATP. The samples
were then illuminated with a UV lamp assembly (365-nm wavelength) for 10 min
on ice (4°C) as described previously (45). Following SDS-PAGE on an 8%
Tris-glycine gel at constant voltage, the gels were dried and exposed to Bio-Max
MR film at 80°C for 12 to 24 h. The radioactivity incorporated into the Cdr1p
band was quantified as described above.
RESULTS
The Candida drug resistance protein (Cdr1p), a member of
the ABC superfamily, causes MDR by an active efflux mech-
anism, which keeps the intracellular level of antimycotic com-
pounds, such as azoles, below a cell-killing threshold. Similar
to other well-characterized multidrug ABC transporters,
Cdr1p (170 kDa) comprises two NBDs and 12 TMSs. NBDs
are the hub of ATP hydrolysis activity and are considered
critical for ABC protein-mediated drug efflux. In an attempt to
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functionally characterize the Cdr1p in terms of drug and nu-
cleotide binding and the importance of domains in drug inter-
actions, in this study we have overexpressed Cdr1p as a GFP-
tagged protein. The functional characterization of wild-type
Cdr1p-GFP and of the mutant variants generated by site-di-
rected mutagenesis are the subject of the following experi-
ments.
Overexpressed Cdr1p-GFP is fully functional. In order to
confirm the PM localization of Cdr1p and for biochemical
characterization, we used an expression system developed by
Nakamura et al. (33), which was a generous gift from R. D.
Cannon, where Cdr1p was stably overexpressed from a
genomic PDR5 locus in an S. cerevisiae mutant, AD1-8u. The
AD1-8u mutant was derived from a pdr1-3 mutant strain with
a gain-of-function mutation in the transcription factor Pdr1p,
resulting in a constitutive hyperinduction of the PDR5 pro-
moter. The high-level expression of Cdr1p was obtained by
integration of the CDR1 ORF to the PDR5 promoter in AD1-
8u, and the resulting strain was designated AD1002 (33). We
tagged the GFP gene at the C-terminal end of CDR1, which
was overexpressed as a fusion protein in the PSCDR1-GFP
strain (Fig. 1a). A single-copy integration of GFP-tagged
CDR1 was ensured by Southern hybridization of restricted
genomic DNA with a CDR1-specific probe as described earlier
(33) (data not shown).
The presence of larger amounts of Cdr1p and Cdr1p-GFP in
the purified PM fractions of AD1002 and PSCDR1-GFP cells
could be detected on an SDS-polyacrylamide gel when stained
by Coomassie brilliant blue G250 dye (Fig. 1b), which was
further confirmed by Western blot analysis of the PM proteins
using Cdr1p polyclonal antibody. Figure 1c confirms that the
Cdr1p and Cdr1p-GFP were expressed in PM fractions to the
same levels. There was an expected 30-kDa difference in the
observed molecular mass of Cdr1p-GFP compared to that of
Cdr1p because of the GFP tag attached to the C-terminal end
of Cdr1p (Fig. 1c). The Pma1 antibodies were used as a PM
marker to check the purity of the purified membranes (Fig.
1d). The intrinsic fluorescence of GFP imparted to the fusion
protein also enabled us to detect the wild-type and mutant
Cdr1p proteins in live cells. Cdr1p-GFP expression at the cell
periphery also confirmed that the GFP tagging of Cdr1p did
not interfere with its localization (data not shown). The ex-
pression of Cdr1p-GFP was further confirmed by fluorescence-
activated cell sorting (FACS) analysis in which Cdr1p-GFP
variant cells showed enhanced fluorescence intensity (Fig. 1e).
We ensured that GFP tagging and overexpression did not
impair functional activity by analyzing drug susceptibilities of
cells harboring CDR1 or the GFP-tagged variant. It was found
that the cells expressing Cdr1p or Cdr1p-GFP had similar
levels of resistance to the drugs tested (Fig. 1f). The purified
PM from PSCDR1-GFP cells containing Cdr1p-GFP also
showed oligomycin-sensitive ATPase activity which was almost
threefold higher (and comparable to the activity of overex-
pressed Cdr1p) than the activity of the PM protein isolated
from the AD1-8u control cells (Fig. 1g). Taken together, it
was thus established that overexpressing Cdr1p and its GFP-
tagged variant is properly localized and functional. In the fol-
lowing experiments, these proteins were further examined for
drug- and nucleotide-binding properties.
Photoaffinity analogues of ATP and drug substrates bind to
Cdr1p. Cdr1p utilizes ATP as an energy source by catalyzing its
hydrolysis and coupling the energy released to the efflux of the
drugs. Therefore, the binding of ATP to this protein can also
be checked as a means of determining the functionality of this
protein. The photoaffinity analogue, [-32P]8-azido-ATP, has
been used routinely for studying the interactions of nucleotide
with the human P-gp, MRP1, and other ABC transporter pro-
teins (4, 12, 45). The binding of [-32P]8-azido-ATP to Cdr1p
was examined to see the interactions of ATP with the protein
as detailed in Materials and Methods. Figure 2a shows that the
incubation of purified PM proteins (15 g) from AD1-8u,
AD1002, and PSCDR1-GFP cells with 10 M [-32P]8-azido-
ATP (10 Ci/nmol) followed by UV irradiation led to covalent
incorporation of this analogue (Fig. 2a, lane 3). The labeling
was competed out by 1,000-fold excess ATP (10 mM), confirm-
ing that the observed binding was specific (Fig. 2a, lane 4). The
binding of [-32P]8-azido-ATP to the Cdr1p-GFP variant pro-
tein was similar to that of native Cdr1p, which was also com-
peted out by excess ATP (Fig. 2a, lanes 5 and 6). The control
PM fraction from AD1-8u cells did not show any band at the
corresponding position (Fig. 2a, lanes 1 and 2). The specificity
of 8-azido-ATP-, IAAP-, and azidopine-labeled bands (de-
scribed below) corresponding to Cdr1p and Cdr1p-GFP in Fig.
2 was ensured by Western blot analysis. The PM fraction la-
beled with either photoreactive analogue and/or substrate was
run on a gel, which was then transferred to a nylon membrane.
The blot was probed with Cdr1p antibodies, and the same blot
was used to expose X-ray film. The film was overlaid with the
blot to confirm that the bands corresponded to Cdr1p and
Cdr1p-GFP (data not shown). The binding of 8-azido-ATP
analogue confirmed that Cdr1p or its variant Cdr1p-GFP over-
expressed in this heterologous system is functionally active in
terms of its ability to bind ATP.
In order to monitor drug-binding sites on human P-gp, ra-
diolabeled photoactive analogs of prazosin and dihydropyri-
dine have been used successfully (16, 6). Such studies have
revealed two major areas, one on each homologous half of the
protein, as primary sites of drug interaction (6). In this study,
we used IAAP for analyzing interactions with Cdr1p. To ana-
lyze interactions with Cdr1p, 15 g of purified PM proteins
from AD1-8u, AD1002, and PSCDR1-GFP cells was incu-
bated with 3 to 6 nM [125I]IAAP at room temperature for 5
min followed by UV cross-linking as detailed in Materials and
Methods. Figure 2b (lane 2) shows that while IAAP specifically
labeled Cdr1p, there was no binding of IAAP to the PM frac-
tion prepared from control AD1-8u cells (Fig. 2b, lane 1).
The binding of IAAP of Cdr1p-GFP variant PM was similar to
that of native Cdr1p (Fig. 2b, lane 3). In order to test whether
the IAAP binding was specific, we performed binding with
Cdr1p-GFP in the presence of molar excess cycloheximide,
nystatin, anisomycin, and miconazole. Interestingly, IAAP was
competed out by nystatin (100 M), a known substrate of
Cdr1p (Fig. 2c, lane 4), while the binding remained unaffected
by the presence of the other drugs (Fig. 2c, lanes 3, 5, and 6).
Azidopine, a dihydropyridine photoaffinity analog, has been
shown to bind specifically to mammalian drug-transporting
P-gps (37, 20, 26, 27) and is a valuable tool used in determining
the substrate-binding sites on these multidrug transporters. We
explored this possibility by examining the ability of azidopine
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to bind to Cdr1p. The PM proteins (30 g) from AD1-8u,
AD1002, and PSCDR1-GFP cells were incubated with 0.5 M
[3H]azidopine for 5 min at room temperature and then photo-
cross-linked. The incorporation of radioactivity in protein
bands corresponding to Cdr1p and Cdr1p-GFP showed similar
intensities, implying that [3H]azidopine could bind to both
proteins (Fig. 2e). The specificity of binding was assessed by
the addition of a 100 M concentration of cycloheximide,
nystatin, anisomycin, or miconazole. Interestingly, [3H]azido-
pine binding to Cdr1p-GFP was not inhibited by nystatin, as
was the case with IAAP binding, but was instead found to be
competed out by miconazole (Fig. 2f). Of note, the competi-
FIG. 1. Comparison of Cdr1p and Cdr1p-GFP localization and functions. (a) Cartoon showing the overexpression cassette of Cdr1p-GFP. A
gain-of-function mutation in the transcription factor genes PDR1 and PDR3 resulted in a constitutive hyperinduction of the PDR5 promoter. CDR1
with a GFP tag at the C-terminal end was integrated under the control of this promoter, which resulted in the overexpression of Cdr1p-GFP. (b
and c) Expression of Cdr1p and Cdr1p-GFP in S. cerevisiae AD1-8u cells. The PM proteins (20 g) from AD1-8u, AD1002 (wild-type Cdr1p),
and PSCDR1-GFP (Cdr1p-GFP) cells were separated on an SDS–8% polyacrylamide gel (b), stained with colloidal Coomassie blue G-250 (c),
electroblotted onto a nitrocellulose membrane and incubated with rabbit polyclonal anti-Cdr1p antibody (diluted 1:500). Proteins were detected
with HRP-labeled anti-rabbit immunoglobulin using an ECL kit. (d) Expression of Pma1p. The PM proteins (20 g) from AD1-8u, AD1002
(wild-type Cdr1p), and PSCDR1-GFP (Cdr1p-GFP) cells were separated on an SDS–8% polyacrylamide gel and probed with rabbit polyclonal
anti-Pma1p antibody (diluted 1:10,000) to detect Pma1p expression as described above. The position of the corresponding 100-kDa band of Pma1p
on the gel is marked by an arrow. (e) Flow cytometry of cells expressing Cdr1p-GFP. AD1-8u (control) and PSCDR1-GFP (Cdr1p-GFP) cells
were grown to mid-log phase and used for FACS analysis as detailed in Materials and Methods. Analysis was performed with CellQuest software
as described previously (44). (f) Drug resistance profiles of AD1-8u, PSCDR1-GFP, and AD1002 cells. The MIC80s (in micrograms per milliliter)
of the indicated drugs, anisomycin (Aniso), cycloheximide (Cyh), fluconazole (Flu), miconazole (Mic), and nystatin (Nys), for AD1-8u,
PSCDR1-GFP (Cdr1p-GFP), and AD1002 (wild-type Cdr1p) cells were determined as described in Materials and Methods. The results are typical
of one determination, which was confirmed by three independent experiments. (g) Oligomycin-sensitive Cdr1p ATPase activity in purified PMs
from AD1-8u, PSCDR1-GFP (Cdr1p-GFP), and AD1002 (wild-type Cdr1p) cells. ATPase assay was performed by using PM proteins (100 g/ml)
of AD1-8u, AD1002, and PSCDR1-GFP cells at 30°C for 10 min as described in Materials and Methods. The oligomycin-sensitive activity was
determined as the difference in the ATPase activity in the presence or absence of 20 M oligomycin. The values are given as the means	 standard
deviations (error bars) for three independent experiments.
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FIG. 2. [-32P]8-azido-ATP, [125I]IAAP, and [3H]azidopine bind specifically to Cdr1p and Cdr1p-GFP. (a) Binding of [-32P]8-azido-ATP to
Cdr1p and Cdr1p-GFP. The PM proteins (300 g/ml) were photoaffinity labeled with 10 M [-32P]8-azido-ATP (10 Ci/nmol) under subdued
light as described in Materials and Methods. Ice-cold ATP (10 mM) was added to displace excess bound [-32P]8-azido-ATP where indicated. Lane
1, AD1-8u cells; lane 2, AD1-8u cells plus 10 mM ATP; lane 3, AD1002 cells; lane 4, AD1002 cells plus 10 mM ATP; lane 5, PSCDR1-GFP
cells; lane 6, PSCDR1-GFP cells plus 10 mM ATP. (b) Binding of [125I]IAAP to Cdr1p and Cdr1p-GFP. The PM proteins (300 g/ml) from
AD1-8u (lane 1), AD1002 (lane 2), and PSCDR1-GFP (lane 3) cells were incubated with 3 to 6 nM [125I]IAAP (2200 Ci/mmol) for 5 min under
subdued light and processed as described in Materials and Methods. (c) Effects of Cdr1p substrates on the binding of IAAP to Cdr1p-GFP. The
PM proteins (15 g/50 l) from AD1-8u (control) (lane 1) or PSCDR1-GFP (lanes 2 to 6) cells were incubated with 100 M concentrations of
the following drug substrates for 10 min at 37°C in 50 mM Tris-HCl (pH 7.5). Lane 2, no drug; lane 3, cycloheximide; lane 4, nystatin; lane 5,
anisomycin; lane 6, miconazole. The samples were brought to room temperature, and 3 to 6 nM [125I]IAAP (2200 Ci/mmol) was added and
incubated for an additional 5 min under subdued light. The samples were then illuminated with a UV lamp (365-nm wavelength) for 10 min and
processed as described in Materials and Methods. (d) Concentration-dependent inhibition of IAAP binding to Cdr1p-GFP by nystatin. The PM
proteins (15 g/50 l) of PSCDR1-GFP cells were incubated with increasing concentrations (0.25 to 50 M) of nystatin for 10 min at 37°C in 50
mM Tris-HCl (pH 7.5). The samples were brought to room temperature, and 3 to 6 nM [125I]IAAP (2200 Ci/mmol) was added and incubated for
an additional 5 min under subdued light. The samples were processed and the radioactivity incorporated into the Cdr1p band was quantified as
described in Materials and Methods. The data were fitted using the software GRAPHPAD PRISM 2.0 for the PowerPC Macintosh and are
representative of three independent experiments. (e) Photoaffinity labeling of Cdr1p and Cdr1p-GFP with [3H]azidopine. The PM proteins (30 g)
from AD1-8u (lane 1), AD1002 (lane 2), and PSCDR1-GFP (lane 3) cells were incubated with 0.5 M [3H]azidopine (60 Ci/mmol) for 5 min
under subdued light. The samples were processed and analyzed as described in Materials and Methods. (f) Effects of Cdr1p substrates on the
binding of [3H]azidopine to Cdr1p-GFP. The PM proteins (30 g) of AD1-8u (control) (lane 1) or PSCDR1-GFP (lanes 2 to 6) cells were
incubated with 100 M concentrations of the following drug substrates for 10 min at 37°C in 50 mM Tris-HCl (pH 7.5). Lane 2, no drug; lane 3,
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tion by both the substrates was concentration dependent,
which showed saturation and thus was specific. We used sub-
strate concentrations for routine experiments, which showed
maximum inhibition or competition (Fig. 2d and g).
Construction and expression of mutant variants of Cdr1p.
A multiple-sequence alignment of human P-gp, the ABC drug
transporter of S. cerevisiae (Pdr5p), and C. albicans Cdr1p,
Cdr2p, Cdr3p, and Cdr4p highlights the conservation of certain
amino acid residues within TMSs and NBDs which may have a
role in the functioning of these transporters (Fig. 3a). Consid-
ering the functional importance of amino acid residues deter-
mined for other ABC drug transporters, particularly of human
P-gp and Pdr5p of S. cerevisiae, in this study we selected the
equivalent of the most homologous or conserved residues of
Cdr1p for point mutations (Fig. 3b) as indicated. This was
achieved either by replacing a conserved residue by another
amino acid, such as in SS1, SS2, SS3, SS4, SS5, SS7, SS8, SS9,
SS10, SS11, SS12, SS13, SS14, SS15, SS16, SS17, or SS18, or by
deleting the residue altogether, as in SS6. In total, 18 muta-
tions (SS1 to SS18) were introduced in the different predicted
domains spanning the entire length of Cdr1 and are high-
lighted in Fig. 3b.
Initially, all the mutations were introduced into the CDR1
gene driven by its native promoter cloned in nonintegrative
pYEURA3 plasmid (pS12-35) (36). The hypersensitive
AD1234568 cells were then transformed with the mutated
plasmids, and the positive clones were selected by their ability
to grow on SD-URA plates. The positive transformants were
further confirmed by Southern hybridization (data not shown).
At least two positive clones of every mutant were selected for
initial screening to rule out clonal variations.
Drug resistance profiles of mutant Cdr1ps. Confirmed pos-
itive mutants designated SS1 to SS18 were screened for their
sensitivity to drugs by determining the lowest drug concentra-
tion that gave 
80% inhibition (MIC80) (Table 2) and also by
spot test (Fig. 4). The mutants were classified into three groups
according to their sensitivity to the drugs tested. Substitutions
such as D232K (SS10) and T1351F (SS15) and deletion of
phenylalanine, F774 (SS6), resulted in a general drug-sensi-
tive phenotype towards all the drugs tested, while strains with
mutations F774A (SS5), G296D (SS11), G995S (SS12),
G1000C (SS14), C1418Y (SS16), T1449I (SS17), and V1456I
(SS18) were selectively sensitive to one or more drugs com-
pared to the wild type. Mutants, such as K309E (SS1), R308S
(SS2), G305A (SS3), G305V (SS4), V773A (SS7), V773I (SS8),
D232E (SS9), and G998S (SS13), retained the hyperresistant
phenotype comparable to wild-type Cdr1p-expressing cells
(AD-CDR1).
In order to ascertain whether the introduced mutation in
Cdr1p and the observed altered drug susceptibility were not
due to poor expression or localization of the protein, we ana-
lyzed its expression in PM proteins by immunoblotting. It was
observed that all the mutants except F774 (SS6) (discussed
below) expressed the mutant variants of Cdr1ps to the same
level (data not shown).
As shown in Fig. 4 and Table 2, the mutant variant SS5
(F774A) was sensitive to nystatin, cycloheximide, and flucon-
azole but showed marginal or no alterations in drug suscepti-
bilities towards other drugs tested (Table 2). However, the
Cdr1p-harboring F774 variant in SS6 was found to be sensi-
tive to all the drugs tested.
Site-directed mutagenesis in the overexpressed Cdr1p. In
order to understand the molecular bases of the observed phe-
notypes of the two variant mutant Cdr1p-expressing cells (SS5
[F774A] and SS6 [F774]), they were analyzed further in
greater detail. To do this, the same mutations were introduced
in the Cdr1p-GFP-overexpressing plasmids (pPSCDR1-GFP).
The mutated plasmids were integrated in S. cerevisiae (AD1-
8u) as described above. Southern hybridization was done
using a CDR1-specific probe to ensure that the gene was in-
serted as a single copy at the genomic PDR5 locus (data not
shown). The new overexpressing strains harboring mutant
Cdr1p-GFP were designated SS5G (F774A) and SS6G
(F774).
Drug susceptibility of SS5G (F774A) and SS6G (F774).
The cells overexpressing GFP-tagged Cdr1p variants were
checked for their sensitivity to drugs. As shown in Table 3, the
SS6G (F774) strain was significantly sensitive to all drugs
tested, while the SS5G (F774A) strain showed significant sen-
sitivity to only nystatin. It should be pointed out that the
difference in the fold sensitivity or resistance depicted in Ta-
bles 2 and 3 cannot be compared due to different expression
strategies employed in these experiments (Table 2 depicts data
of a low-copy-number plasmid expression system, while Table
3 shows MICs of an integrative overexpression system).
ATPase activity of mutant Cdr1p-GFPs. The purified PM
proteins from SS5G (F774A) and SS6G (F774) cells were
analyzed for their oligomycin-sensitive ATPase activity. Of
note, the oligomycin-sensitive ATPase activity was higher in all
the PM fractions from cells expressing either native or mutant
Cdr1p-GFP than in control AD1-8u cells (Fig. 5a). However,
the oligomycin-sensitive ATPase activity of SS5G (F774A) was
comparable to that of native Cdr1p-GFP, while the specific
activity of SS6G (F774) was 50% lower (Fig. 5a). However,
considering the fact that the expression of the mutant Cdr1p-
GFP in SS6G (F774) was 5% of the wild-type Cdr1p-GFP
(Fig. 6a), the specific activity of mutant protein could actually
be higher. It is important to mention that we were unable to
detect drug-stimulated ATPase activity, although that would
have been a correct measure of the ATPase activity contrib-
uted by the active protein. In fact, we and others have so far
been unable to demonstrate drug-stimulated ATPase activity
of any of the yeast ABC drug transporters (10, 33).
cycloheximide; lane 4, nystatin; lane 5, anisomycin; lane 6, miconazole. The samples were brought to room temperature, and 0.5 M [3H]azidopine
was added and incubated for an additional 5 min, and the samples were processed as described in Materials and Methods. (g) Concentration-
dependent inhibition of [3H]azidopine binding to Cdr1p-GFP by miconazole. The PM proteins (30 g) from PSCDR1-GFP cells were incubated
with increasing concentrations (0.25 to 100 M) of miconazole for 10 min at 37°C. The samples were brought to room temperature, and 0.5 M
[3H]azidopine was added and incubated for an additional 5 min. The samples were processed and quantitated as described in Materials and
Methods and the legend to Fig. 2d.
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FIG. 3. Alignment of protein sequences of various domains and the positions of mutations in a predicted two-dimensional topology model of
Cdr1p. (a) The alignment of the highly conserved regions NBDs, TMS6, CL5, and EL6 of human Mdr1, Cdr1, Cdr2, Cdr3, Cdr4, and Pdr5 proteins.
The amino acids are numbered according to their positions in the proteins. The positions of mutated residues in Cdr1p with respect to other
proteins are marked with arrows, and the residues mutated in Cdr1p are boxed. Since there is no homology in the protein sequences of Mdr1 and
Cdr1 to Cdr4 proteins in CL5 and EL6, the Mdr1 protein sequence has not been included in these alignments. (b) Locations of the mutations
introduced into CDR1. The amino acid substitutions introduced by site-directed mutagenesis, the designation, and the location of mutation are
indicated in the predicted topology model in Cdr1p. The mutants, which were tagged with GFP at the C-terminal end and overexpressed in S.
cerevisiae, are boxed.
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Mutant Cdr1p-GFPs elicit reduced efflux of rhodamine 6G.
We checked the rhodamine 6G efflux and found that both the
mutants overexpressing GFP-tagged Cdr1p variants exhibited
reduced efflux compared to cells expressing native protein.
(Fig. 5b).
Expression of mutant Cdr1p-GFPs. In order to ensure that
the observed changes in drug susceptibilities and efflux activi-
ties of SS5G (F774A) and SS6G (F774) were due to alter-
ations in protein functions rather than due to altered expres-
sion levels, the steady-state levels of Cdr1p-GFP variants were
compared to those of the native protein by Western blot anal-
ysis. The Western blot of these two overexpressing mutant
Cdr1p-GFP PM proteins with anti-Cdr1p polyclonal antibody
showed that SS5G (F774A) expressed mutant Cdr1p-GFPs to
the same level as that of wild type (Fig. 6a, middle panel).
FIG. 4. Drug resistance profiles of wild-type and mutant CDR1 strains determined by the spot and MIC assays. S6-20 (control) or AD-CDR1
(expressing wild-type Cdr1p) cells or the Cdr1p mutants (SS1 to SS18) created by site-directed mutagenesis were grown overnight on SD-URA
plates at 30°C. The cells were then resuspended in PBS to an A600 of 0.1. Five microliters of fivefold serial dilutions, namely, 1:5 (lanes 1), 1:25
(lanes 2), 1:125 (lanes 3), and 1:625 (lanes 4) dilutions of each strain were spotted onto SD-URA plates in the absence (control) or presence of
the following drugs: anisomycin (Aniso) (1 g/ml), cycloheximide (Cyh) (20 ng/ml), fluconazole (Flu) (2 g/ml), miconazole (Mic) (250 ng/ml),
and nystatin (Nys) (500 ng/ml). Growth differences were recorded after incubation of the plates for 48 h at 30°C. Growth was not affected by the
presence of the solvents used for the drugs (data not shown).
TABLE 2. Drug susceptibility of S. cerevisiae cells expressing the
wild type and mutant variant of Cdr1p
Strain Amino acidchange
MICa (g/ml)
Aniso Cyh Flu Mic Nys
SS1 K309E 8 0.15 16 2 0.5
SS2 R308S 16 0.075 16 2 0.5
SS3 G305A 16 0.15 32 4 0.25
SS4 G305V 8 0.15 32 4 0.5
SS5 F774A 16 0.037 8 4 0.12
SS6 F774 4 0.018 4 0.5 0.03
SS7 V773A 16 0.15 32 8 1
SS8 V773I 16 0.15 32 16 1
SS9 D232E 16 0.15 64 16 1
SS10 D232K 2 0.018 4 1 0.03
SS11 G296D 8 0.037 8 0.5 0.5
SS12 G995S 8 0.037 8 8 0.5
SS13 G998S 32 0.075 64 32 1
SS14 G1000C 16 0.075 128 0.5 1
SS15 T1351F 0.5 0.008 8 0.12 0.03
SS16 C1418Y 32 0.15 64 1 1
SS17 T1449I 8 0.15 64 1 0.5
SS18 V1456I 16 0.075 64 1 0.5
S6-20 1 0.004 2 0.25 0.015
AD-CDR1 32 0.3 64 8 1
a MICs were determined by a microdilution method as described in Materials
and Methods. Aniso, anisomycin; Cyh, cycloheximide; Flu, fluconazole; Mic,
miconazole; Nys, nystatin. The MIC test end point was defined as the MIC80.
TABLE 3. Drug susceptibility of S. cerevisiae cells overexpressing
the wild type and mutant variant of Cdr1p
Strain
MICa (g/ml)
Aniso Cyh Flu Mic Nys
AD1-8u 0.12 0.015 1 0.015 0.03
PSCDR1-GFP 16 1 64 4 2
SS5G (F774A) 8 0.5 16 1 0.25
SS6G (F774) 0.12 0.015 2 0.015 0.03
a MICs were determined by a microdilution method as described in Materials
and Methods. Aniso, anisomycin; Cyh, cycloheximide; Flu, fluconazole; Mic,
miconazole; Nys, nystatin. The MIC test end point was defined as the MIC80.
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Hence, the observed functional defects observed in SS5G
(F774A) expressing a mutant variant of Cdr1p were not due to
an effect on the level of the synthesis or trafficking of these
proteins. The PM fractions were probed for PM-ATPase with
its antibodies on a Western blot, which showed equal amounts
of protein in all the PM fractions (Fig. 6a, lower panel). As
revealed by immunoblotting with a monoclonal antibody
against GFP, the mutant Cdr1p-GFP of SS6G (F774) was
poorly expressed at the cell surface (Fig. 6a, upper panel, lane
4). Of note, this faint band of mutant Cdr1p-GFP from SS6G
was picked up consistently when we used monoclonal antibody
against GFP. The FACS analysis of the SS6G (F774) cells
also showed poor cellular expression of mutant Cdr1p-GFP
(Fig. 6b). Confocal microscopy confirmed that there was con-
siderably reduced cell surface expression of mutant Cdr1p-
GFP in SS6G (F774) cells (Fig. 6c). Thus, F774 Cdr1p-GFP
mutant variant protein was consistently detected at a reduced
steady-state level on the cell surface relative to native Cdr1p-
GFP, suggesting that this mutation might harbor a defect
which affects its surface localization (discussed below).
Characterization of ATP- and substrate-binding sites of mu-
tant Cdr1p-GFP variants. In order to explore whether the
observed differences in drug susceptibilities accompanied by
increased drug sensitivity and efflux activities were not due to
any aberration in nucleotide or drug binding, these mutants
were analyzed for their ATP- and drug-binding abilities by
using [-32P]8-azido-ATP, [125I]IAAP, and [3H]azidopine.
[-32P]8-azido-ATP binding. The radiolabeled analogue of
ATP, [-32P]8-azido-ATP, was used to assess its binding to
mutant Cdr1p-GFPs using the purified PM fractions from
SS5G (F774A) and SS6G (F774) cells. It is clear from Fig. 6d
that there was no significant difference in the ATP binding to
FIG. 5. Functional characterization of the Cdr1p-GFP and mutant Cdr1p-GFPs. (a) Oligomycin-sensitive ATPase activity in the PM proteins
of cells expressing wild-type and mutant Cdr1p-GFPs. The ATPase activity of the wild-type and mutant SS5G (F774A) and SS6G (F774)
Cdr1p-GFPs was determined in the PM fraction as described in the legend to Fig. 1g. The results are the means 	 standard deviations (error bars)
for three independent experiments. (b) Rhodamine 6G efflux from the wild-type, SS5G (F774A), and SS6G (F774) cells. Rhodamine 6G efflux
from AD1-8u, wild-type, SS5G (F774A), and SS6G (F774) cells was determined as described in Materials and Methods. The values are the
means 	 standard deviations (error bars) for four independent experiments.
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the PM fraction of wild type and SS5G (F774A) cells. There
was very little binding of [-32P]8-azido-ATP to the PM of
SS6G (F774) cells, which correlated well with its poor expres-
sion in these cells. The binding of [-32P]8-azido-ATP was,
however, specific in all the mutants carrying Cdr1p variants, as
was evident from its competition by ATP (10 mM) (Fig. 6d).
[125I]IAAP and [3H]azidopine binding to mutant Cdr1p-
GFPs. It was found that although mutant Cdr1p-GFP of SS5G
(F774A) could bind [125I]IAAP, the variant showed 2.3-fold-
greater binding than the native Cdr1p-GFP (Fig. 6e).
[125I]IAAP binding was considerably lower in SS6G (F774)
cells. Further, as in the case of native Cdr1p, [125I]IAAP bind-
ing was also competed out by nystatin (100 M) for the mu-
tants.
The drug-binding domains of mutant Cdr1ps were further
probed by examining the binding of [3H]azidopine. It was ob-
served that although [3H]azidopine binds to mutant Cdr1p-
GFP from SS5G (F774A), [3H]azidopine binding to mutant
FIG. 6. Expression of mutant Cdr1p-GFPs and ATP- and substrate analog-binding characteristics, localizations, and FACS analysis of mutant
Cdr1p-GFPs. (a) Expression of Cdr1p-GFP and mutant Cdr1p-GFPs in S. cerevisiae. The PM proteins (20 g) from AD1-8u (lane 1),
PSCDR1-GFP (lane 2), SS5G (F774A) (lane 3), and SS6G (F774) (lane 4) cells were separated on an SDS–8% polyacrylamide gel, electroblotted
onto a nitrocellulose membrane, and incubated with mouse monoclonal anti-GFP antibody (diluted 1:1,000) (upper panel), rabbit polyclonal
anti-Cdr1p antibody (diluted 1:500) (middle panel), and rabbit polyclonal anti-Pma1p antibody (diluted 1:10,000) (lower panel). Proteins were
immunodetected as described in Materials and Methods. (b) Flow cytometry of S. cerevisiae SS5G (F774A) and SS6G (F774) cells. The flow
cytometry of the S. cerevisiae cells was performed as described in the legend to Fig. 1e. The histogram derived from the CellQuest program depicts
fluorescence intensities for AD1-8u (control) (purple), SS5G (F774A) (orange), SS6G (F774) (blue), and PSCDR1-GFP (green) cells. (c)
Confocal pictures of S. cerevisiae cells expressing GFP-tagged wild-type and mutant Cdr1ps SS5G (F774A) and SS6G (F774). Cells were grown
in SD-URA medium to late log phase. The cells were washed and resuspended in an appropriate volume of 50 mM HEPES (pH 7.0). The cells
were directly viewed on a glass slide with a drop of antifade reagent to prevent photobleaching, with a 100 oil immersion objective on a Bio-Rad
confocal microscope (MRC 1024). (d) [-32P]8-azido-ATP labeling of AD1-8u (control), wild-type, SS5G (F774A), and SS6G (F774) mutant
Cdr1p-GFPs. The PM proteins (15 g/50 l) were photoaffinity labeled with 10 M [-32P]8-azido-ATP (10 Ci/nmol) in the absence () or
presence () of 10 mM ATP as described in Materials and Methods. (e) [125I]IAAP labeling of AD 1-8u (control [C]), wild-type (Cdr1p-GFP),
and mutant Cdr1p-GFP from SS5G (F774A) and SS6G (F774). The PM proteins (15 g) were labeled with 3 to 6 nM [125I]IAAP (2,200 Ci/mmol)
and competed as described in Materials and Methods. A 100 M concentration of nystatin as indicated () was added to compete IAAP binding.
(f) [3H]azidopine labeling of AD1-8u (control [C]) and wild-type (Cdr1p-GFP) cells and mutant Cdr1p-GFPs from strains SS5G (F774A) and
SS6G (F774). The PM proteins (30 g) were labeled with [3H]azidopine as described in Materials and Methods in the presence () or absence
() of 100 M miconazole as indicated.
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Cdr1p-GFP from SS5G (F774A) was 1.8-fold higher than that
for wild-type Cdr1p-GFP (Fig. 6f). On the other hand, the
mutant Cdr1p-GFP from SS6G (F774) showed a very faint
specific band, which corresponded to very little protein at the
cell surface of this mutant protein. Irrespective of the extent of
[3H]azidopine binding among mutant variants of Cdr1p-GFP,
it could be competed out by miconazole (100 M).
The deletion of F774 leads to poor cell surface localization
of the mutant Cdr1p-GFP in SS6G. The confocal images
showed that while the expression of Cdr1p-GFP in the wild-
type cells and of mutant Cdr1p-GFP in SS5G (F774A) cells at
the cell surface (Fig. 6c) was comparable, it was minimal in
SS6G (F774) cells. Although some of the fluorescent protein
was visible in the cytoplasm of SS6G (F774) cells, very small
patches of fluorescence were seen on the cell surface, which
showed that probably the mutant Cdr1p-GFP in SS6G (F774)
cells was not properly localized on the cell surface. These
results were corroborated by Western blot analysis where PM
of SS6G (F774) cells also showed significantly reduced ex-
pression of mutant Cdr1p-GFP (Fig. 6a). FACS analysis of the
live cells showed fluorescence in SS5G (F774A) cells that was
comparable to that of the wild-type PSCDR1-GFP cells. SS6G
(F774) cells, however, showed lower fluorescence intensity,
but it was still higher than that of the control cells (AD1-8u)
(Fig. 6b). The mean fluorescence intensities (in arbitrary units)
for wild-type PSCDR1-GFP, SS5G (F774A), SS6G (F774),
and AD1-8u cells were 500, 482, 160, and 11, respectively.
Taken together, these results suggest that there was only mar-
ginal expression of mutant Cdr1p-GFP in the PM of SS6G
(F774) cells, which was probably sufficient to show some
functional activity (Fig. 5a and b and Fig. 6); the functional
activity was lower than that of the wild type but not sufficient
to confer drug resistance (Fig. 4 and Table 2).
Mutant F774 Cdr1p-GFP can be brought to the cell sur-
face by growing cells in the presence of the Cdr1p substrate. In
the following experiment, we explored various possibilities re-
lated to poor surface expression of the SS6G (F774) protein
variant. The poor surface expression of the SS6G (F774)
protein could be due either to poor localization, reduced ex-
pression of protein, or rapid degradation of protein. We
checked whether the localization of mutant Cdr1p-GFP in
SS6G (F774) cells could be improved. To do this, we added
different drugs, which are substrates of Cdr1p, such as cyclo-
heximide, miconazole, anisomycin, and nystatin (at concentra-
tions lower than their respective MICs), just after the lag phase
of the SS6G (F774) cells (4 to 5 h). The cells were then grown
for 12 more hours. Thereafter, cells were checked by confocal
microscopy for the localization of the protein. It was observed
that the mutant Cdr1p-GFP protein showed improved surface
localization with increasing concentrations of cycloheximide.
The surface expression of mutant Cdr1p-GFP was almost iden-
tical to that of native Cdr1p-GFP at 40 ng of cycloheximide per
ml (Fig. 7a to h). FACS analysis also confirmed that the surface
expression of SS6G (F774)-expressing Cdr1p-GFP mutant
grown in the presence of 40 ng of cycloheximide per ml was
similar to that of the wild type (Fig. 7i). Interestingly, PM
protein isolated from the SS6G (F774) cells, which were
grown in increasing concentrations of cycloheximide and sub-
jected to SDS-PAGE and Western blot analysis (probed with
monoclonal anti-GFP antibody), also showed a concentration-
dependent increase in the amount of Cdr1p-GFP in the PM
fraction, which peaked at 40 and 50 ng/ml (Fig. 7j and k, lanes
6 and 7). Under these conditions, SS6G (F774) cells express-
ing mutant variant distinctly showed improvement in surface
localization, while the presence of drug had no effect in cells
expressing native Cdr1p-GFP (Fig. 7b, h, and i). The observed
rescuing effect was not specific to cycloheximide alone. Other
substrates of Cdr1p, such as anisomycin and nystatin, could
also rescue the F774 protein to the PM (data not shown).
Mutant Cdr1p-GFP from SS6G (F774) cells grown in the
presence of cycloheximide is functional. In order to test
whether improved localization led to the resumption of trans-
port functions, the efflux of rhodamine 6G was measured in
cells grown in the presence of cycloheximide. The control
(AD1-8u), PSCDR1-GFP, and SS6G (F774) cells were
grown in the presence or absence of cycloheximide (40 ng/ml)
for 12 to 14 h, and rhodamine 6G efflux was studied as de-
scribed in Materials and Methods. Figure 7l shows that the
SS6G (F774) cells grown in the presence of cycloheximide
showed considerable increase in rhodamine 6G efflux over the
same cells grown in the absence of cycloheximide. The level of
efflux was comparable to that of native PSCDR1-GFP cells
grown at the same concentration of cycloheximide. There was
some reduction in the efflux of rhodamine 6G by PSCDR1-
GFP cells grown in the presence of cycloheximide. The de-
crease in efflux by the cells expressing native Cdr1p could be
due to the fact that cycloheximide, which is also a substrate for
the Cdr1p transporter, probably competes with rhodamine 6G.
DISCUSSION
Cdr1p was first cloned and identified as a protein capable of
effluxing a variety of unrelated cytotoxic drugs and subse-
quently demonstrated to be a transporter involved in azole
resistance of C. albicans (24, 36). Further studies from our
laboratory as well as from other research groups established
that the efflux of drugs by Cdr1p represents one of the major
determinants of azole resistance in clinical isolates of C. albi-
cans (24, 38). Functional analysis of Cdr1p further revealed
that in addition to drug extrusion activity, the protein is also
capable of effluxing human steroid hormones and can translo-
cate membrane phospholipids between the two monolayers of
PM of C. albicans cells (13, 24). The promiscuity of Cdr1p
towards substrates and its ability to mediate several functions
suggest that the protein might contain mutually exclusive sub-
strate-binding sites that allow the efflux of a variety of unre-
lated compounds with striking physical and chemical diversity.
The molecular basis for the broad range of this transport
capacity is largely unknown for Cdr1p as well as for other ABC
drug transporters of yeast. Delineating the architecture of the
drug-binding sites of Cdr1p for the substrates will be invaluable
not only to understand how drugs interact with this protein but
also to design more useful and specific inhibitors of Cdr1p. In
this study, we have attempted to examine the relationship
between structure and function for Cdr1p.
Cdr1p is fully active as a GFP-tagged protein. For detailed
functional analysis, Cdr1p tagged with GFP was overexpressed
from a genomic PDR5 locus in a S. cerevisiae AD1-8u mutant
derived from a pdr1-3 mutant strain with a gain-of-function
mutation in the gene encoding transcription factor PDR1, re-
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sulting in a constitutive hyperinduction of the PDR5 promoter
(33). Thus, Cdr1p-GFP expression driven by hyperinduced
PDR5 promoter provided a sufficient level of expression, con-
firmed by confocal microscopy, flow cytometry analysis, and
immunoblotting, for functional analysis. That GFP-tagged
Cdr1p was functional like native Cdr1p was established by
assaying the MICs of various drugs for S. cerevisiae host cells.
The fluorescence imparted by GFP-tagged Cdr1p visualized
with a confocal microscope confirmed its proper localization to
PM.
Cdr1p harbors multiple drug-binding sites. Cdr1p, Pdr5p,
human P-gp, and some of the MRPs function as drug extrusion
pumps. Cdr1p differs structurally from the human full-length
ABC transporters, since it possesses inverted domain organi-
zation [(NBD-TMD)2] (36) compared to human P-gp [(TMD-
NBD)2] (15). However, for the human ABCG2 (the mitox-
antrone resistance-associated protein MXR, the breast cancer
resistance protein BCRP, or the placenta ABC protein
ABCP), the domain organization of the half transporter is
similar to that of Cdr1p (25), and the functional unit of this
transporter is a dimer [(NBD-TMD)2]. Notwithstanding these
domain-based differences and low level of sequence identity
outside conserved stretches, the binding characteristics of
Cdr1p have many commonalties with those of human P-gp.
The binding of IAAP as well as azidopine to Cdr1p is one such
case of similarity. Both analogues bind to human and murine
drug-transporting P-gps and Cdr1p (this study), where it has
been used to map drug-binding sites (17). The fact that IAAP
binding to Cdr1p is competed out by nystatin, while micon-
azole did not have any effect, and the fact that azidopine
binding is competed out only by miconazole (Fig. 2c and f)
suggest that IAAP and azidopine share two different binding
sites in Cdr1p. We had earlier observed that the deletion of a
79-amino-acid stretch from the C-terminal end, which encom-
passes the TMS12 of this transporter, leads to selective impair-
ment of drug resistance (23). The expression of Cdr1p led to
decreased resistance to nystatin, while resistance to micon-
azole was retained. Recently, by using a variety of novel sub-
FIG. 7. Properties of SS6G (F774) mutant Cdr1p-GFP cells. (a to h) Confocal pictures of AD1-8u cells and cells expressing SS6G (F774)
mutant Cdr1p-GFP grown in the presence of increasing concentrations of cycloheximide. (a) AD1-8u cells; (b) PSCDR1-GFP cells expressing
wild-type Cdr1p-GFP grown with 50 ng of cycloheximide per ml; (c to h) SS6G (F774) cells expressing mutant Cdr1p-GFP grown without
cycloheximide (c) or in the presence of the following concentrations of cycloheximide: 10 ng/ml (d), 20 ng/ml (e), 30 ng/ml (f), 40 ng/ml (g), or 50
ng/ml (h). (i) Flow cytometry of SS6G (F774) cells grown in the presence of cycloheximide. The control (AD1-8u), SS6G (F774), and
PSCDR1-GFP cells grown in the presence or absence of cycloheximide (Cyh) (40 ng/ml) as indicated were analyzed by flow cytometry as described
in Materials and Methods. (j and k) Expression of mutant Cdr1p-GFP from SS6G (F774) cells grown in the presence of cycloheximide. The PM
proteins from AD1-8u (lane 1), SS6G (F774) (lane 2), and SS6G (F774) cells grown in the presence of increasing concentrations of
cycloheximide (lanes 3 to 7) and PSCDR1-GFP cells grown in the presence of cycloheximide (50 ng/ml) (lane 8) were separated on an SDS–8%
polyacrylamide gel and stained with colloidal Coomassie blue G250 (j) or electroblotted onto a nitrocellulose membrane (k) and incubated with
mouse anti-GFP monoclonal antibody (diluted 1:1,000). The SS6G (F774) cells were grown in the presence of the following increasing
concentrations of cycloheximide: 10 ng/ml (lane 3), 20 ng/ml (lane 4), 30 ng/ml (lane 5), 40 ng/ml (lane 6), and 50 ng/ml (lane 7). Proteins were
detected with HRP-labeled anti-mouse immunoglobulin using an ECL kit. (k) Rhodamine 6G efflux from SS6G (F774) cells grown in the
presence of cycloheximide. The rhodamine 6G efflux by AD1-8u, SS6G (F774), and PSCDR1-GFP (with or without cycloheximide) cells was
determined as described in Materials and Methods. The results are the means 	 standard deviations (error bars) for three independent
experiments.
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strates of Pdr5p, Golin et al. (14) have reported that this ABC
drug transporter from S. cerevisiae has at least three drug-
binding sites and suggested that some substrates might even
interact at more than one site. Taken together, our results
suggest that Cdr1p harbors different drug-binding sites, which
recognize structurally dissimilar drugs. Of note, selective sen-
sitivity to nystatin and miconazole revealed upon mutational
analysis further reaffirmed that Cdr1p has multiple drug-bind-
ing sites. While variant F774A retained the resistance to mi-
conazole compared to native Cdr1p, its sensitivity towards nys-
tatin was increased considerably (Fig. 4 and Table 2). This
duality of Cdr1p towards these two drugs can be explained if
one considers different binding sites. Interestingly, a similar
conclusion can be drawn from IAAP and azidopine binding.
While the former gets competed out by nystatin, the latter is
affected by miconazole. Taken together, this would suggest
that nystatin and IAAP share common binding site(s), while
azidopine and miconazole bind to another site. The concept of
multiple drug-binding sites is further illustrated by the fact that
the binding of IAAP and azidopine are not competed out by
drugs, such as cycloheximide, anisomycin, and fluconazole,
which may bind to an as yet unidentified site(s).
Notwithstanding topological differences, the photoaffinity
analogues (IAAP and azidopine) could specifically label Cdr1p
as well as human P-gp. The extent of binding of these photoaf-
finity analogues to Cdr1p revealed even more similarity be-
tween the two ABC drug transporters. For example, both
IAAP and azidopine showed enhanced binding to Cdr1p-GFP
variant of SS5G (F774A). Similar observations were reported
by Chen et al. (7), who observed that the deletion of F335 led
to enhanced IAAP binding to P-gp. In another study, Loo and
Clarke (26) observed that the replacement of F335 by A of
human P-gp also led to enhanced binding of azidopine. Taken
together, these results suggest that F335 in TMS6 of mamma-
lian P-gp and its equivalent F774 in TMS6 of Cdr1p behave
similarly and play an important role in determining substrate
specificity.
F774 in SS6G leads to poor localization of mutated Cdr1p.
In order to analyze some of the interesting mutant variants of
Cdr1p, F774A and F774 mutations were introduced into the
Cdr1p-GFP expression system driven by hyperinduced PDR5
promoter (discussed above) for detailed analysis. It was ob-
served that in the SS6G (F774) strain, in which F774 of the
predicted TMS6 was deleted, showed very low expression of
mutant Cdr1p-GFP in the PM fraction when analyzed by West-
ern blot analysis. While mutant Cdr1p-GFP in SS6G (F774)
cells was poorly expressed in PM fractions isolated from these
cells, Western blotting did not show any steady-state expres-
sion defect in SS5G (F774A) membranes. Confocal micros-
copy and FACS analysis also confirmed poor expression of
SS6G (F774) mutant protein.
Cell surface expression of mutant Cdr1p (F774) protein
could be rescued by growth in the presence of cycloheximide.
In the case of the SS6 mutant, one cannot exclude the possi-
bility of poor protein localization in the PM due to either low
protein levels or its degradation. However, since the protein
can be rescued to the cell surface by growing the mutant cells
in the presence of substrates, such as cycloheximide (at a con-
centration that does not affect growth and protein synthesis), it
is probable that the mutant protein is not properly localized.
Of note, the mutant protein of F774 which could be directed
to the PM in the presence of cycloheximide was not only found
to be at the cell surface but also became functionally active, as
determined by its ability to efflux rhodamine 6G. These results
suggest that the deletion mutation F774 in TMS6 inhibits the
transporter from folding into an active conformation, but the
protein can be made to fold into an active conformation if
synthesized in the presence of cycloheximide.
Earlier misprocessing of ABC transporters has also been
observed. For example, the deletion of phenylalanine 508 in
NBD1 of the cystic fibrosis transport receptor (CFTR) causes
its improper localization on the cell surface (8). Deletion of an
equivalent phenylalanine residue in NBD1 of Yor1p of S. cer-
evisiae also led to a variant protein, which was retained in the
endoplasmic reticulum (21). Interestingly, a number of low-
molecular-weight molecules have been shown to rescue the
processing defect of mutant CFTR protein (5). In addition,
even lower temperatures or the presence of glycerol, trimeth-
ylamine N-oxide, or deuterated water has been shown to res-
cue the F508 CFTR mutant misprocessing phenotype (11,
43). Similarly, the TMS6 mutant of human P-gp expressing
misfolded protein was rescued when grown in the presence of
substrates, such as cyclosporine A, capsaicin, vinblastine, or
verapamil (28). In such rescues, an early interaction between
the drug substrate and TMD is observed; this stabilizes the
folding intermediates in a native conformation, thus escaping
cell quality control mechanism. The exact mechanism by which
cycloheximide rescues the misprocessed F774 mutant variant
of Cdr1p is not clear at present. However, given the clinical
importance of this protein, such residues, which affect the
localization, could be exploited in rationally designing antifun-
gal agents.
Taken together, in this study, we have characterized Cdr1p
by overexpressing it as a GFP-tagged protein in S. cerevisiae.
We show that the photoaffinity analogs IAAP and azidopine
specifically bind to Cdr1p. The analysis of GFP-tagged mutant
variants of Cdr1p revealed that the deletion of a conserved
F774 in predicted TM6 led to poor surface localization of the
protein. The mislocalized F774 mutant Cdr1p could be res-
cued to the PM as a functional transporter by growth in the
presence of a Cdr1p substrate, cycloheximide. In addition, our
study demonstrates that there is a conserved functional homol-
ogy between Cdr1p and human P-gp. For example, similar to
Pgp, TMS6 in Cdr1p also appears to be a major contributor to
drug substrate-binding sites. Considering the clinical impor-
tance of MDR in cancer patients and fungal infections, struc-
ture-and-function study of Cdr1p should provide additional
information about the mechanism of action of these yeast and
mammalian drug transporters.
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